Multiple inflammatory and gout-related targets

Multiple inflammatory and gout-related targets refers to a diverse set of molecular entities involved in the pathophysiology of hyperuricemia and the subsequent inflammatory response to monosodium urate (MSU) crystals. Primary metabolic targets include Xanthine oxidase, an enzyme responsible for uric acid synthesis, and renal transporters such as URAT1 (SLC22A12) and ABCG2, which govern the excretion and reabsorption of urate (StatPearls, 2023). The inflammatory component of gout is driven by the NLRP3 inflammasome, which, upon activation by MSU crystals, facilitates the cleavage and release of the potent pro-inflammatory cytokine Interleukin-1 beta (IL-1β) (Nature Reviews Rheumatology, 2020). Therapeutic strategies target these various points: urate-lowering therapies (ULT) like allopurinol and febuxostat inhibit xanthine oxidase, while uricosurics like lesinurad target URAT1. Acute flares are managed by targeting tubulin with colchicine to inhibit neutrophil chemotaxis, or by using NSAIDs and IL-1 inhibitors to suppress the broader inflammatory cascade (Journal of Inflammation Research, 2021). Additionally, transporters like SLC2A9 (GLUT9) play a significant role in urate homeostasis and are considered potential therapeutic targets. The management of gout thus requires a multi-targeted approach to both lower systemic urate levels and mitigate the intense immune response triggered by crystal deposition.

Other names

Gout-related targetsInflammatory targets in goutUrate-lowering and anti-inflammatory targets

Inhibition of xanthine oxidase to reduce uric acid production; inhibition of URAT1 to increase renal urate excretion; inhibition of tubulin polymerization to prevent neutrophil migration; and antagonism of IL-1 receptors or COX enzymes to reduce inflammation.